HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Brokerages

Shares of HilleVax, Inc. (NASDAQ:HLVX) have received an average rating of “Hold” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $3.00.

Separately, HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a report on Monday.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HLVX. Barclays PLC grew its stake in HilleVax by 14.1% in the 4th quarter. Barclays PLC now owns 47,946 shares of the company’s stock worth $100,000 after acquiring an additional 5,913 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of HilleVax by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock valued at $38,000 after purchasing an additional 6,916 shares during the period. Northern Trust Corp increased its holdings in HilleVax by 2.8% during the 4th quarter. Northern Trust Corp now owns 249,610 shares of the company’s stock worth $517,000 after purchasing an additional 6,916 shares during the period. Ieq Capital LLC increased its holdings in HilleVax by 71.1% during the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock worth $47,000 after purchasing an additional 9,344 shares during the period. Finally, Bank of Montreal Can raised its position in HilleVax by 47.1% during the 4th quarter. Bank of Montreal Can now owns 35,763 shares of the company’s stock valued at $74,000 after purchasing an additional 11,459 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Stock Down 6.6 %

NASDAQ HLVX traded down $0.11 during trading hours on Monday, hitting $1.49. 87,943 shares of the company were exchanged, compared to its average volume of 174,122. HilleVax has a 52 week low of $1.47 and a 52 week high of $16.66. The stock has a 50-day moving average price of $1.82 and a 200 day moving average price of $1.86. The stock has a market cap of $73.96 million, a PE ratio of -0.48 and a beta of 0.76.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). As a group, sell-side analysts anticipate that HilleVax will post -2.64 earnings per share for the current year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.